CD4 and neoplasm: Based on our results, we believe that some of the keys to the success of an immunotherapy targeting MHC-II tumors are (a) proper activation of tumor-specific CD4+ T-cells and (b) identification of potential neo-antigens against which an efficient CD4+ T cell-based response can be induced.